



INTERNATIONAL JOURNAL  
OF PHARMA AND BIO SCIENCES

### ***Internationally Indexed Journal***

Indexed in Chemical Abstract Services(USA),Index Copernicus ,Ulrichs Directory of Periodicals,Google scholar ,Cabi ,DOAJ ,PSOAR, EBSCO ,SCOPUS, EMBASE etc.



### ***Rapid Publishing***

**The International Journal of Pharma and Bio Sciences (IJPBS) is an international journal published quarterly. The Aim of IJPBS is to publish peer reviewed research and review articles in less time without much delay in the developing field of Pharmaceutical and Biological sciences. One week from the date of manuscript submission author gets the decision of acceptance and if accepted the manuscript will be processed within 3 weeks (approx.) for publication.**

#### **Pharmaceutical Sciences**

##### **Branches**

- Pharmaceutics
- Novel drug delivery sys
- Nanotechnology
- Pharmacology
- Pharmacognosy
- Analytical chemistry
- Pharmacy practice
- Pharmacogenomics
- Polymer sciences
- Biomaterial sciences
- Medicinal chemistry
- Natural chemistry
- Biotechnology
- Pharmacoinformatics
- Biopharmaceutics

#### **Biological Sciences**

##### **Branches**

- Biochemistry
- Biotechnology
- Bioinformatics
- Cell biology
- Microbiology
- Allied Sciences
- Molecular biology
- Neurobiology
- Cytology
- Pathology
- Immunobiology



**Impact Factor 0.47\***

*\*Refer Instruction to authors available at [www.ijpbs.net](http://www.ijpbs.net)*



Indexed In Elsevier Bibliographic Database  
(SCOPUS, EMBASE and Sciverse)

Journal Home page  
[www.ijpbs.net](http://www.ijpbs.net)

FOR INSTRUCTION TO AUTHORS VISIT  
[www.ijpbs.net](http://www.ijpbs.net)

- FOR ANY QUERIES EMAIL TO
- [editorofijpbs@yahoo.com](mailto:editorofijpbs@yahoo.com)
  - [editorijpbs@rediffmail.com](mailto:editorijpbs@rediffmail.com)
  - [prasmol@rediffmail.com](mailto:prasmol@rediffmail.com)



## TO STUDY THE HAEMOGLOBINOPATHIES AND RATIO OF COPPER AND ZINC IN SINDHI COMMUNITY OF BHOPAL

**M. KAUR\*<sup>1</sup>, C.B.S.DANGI<sup>1</sup> AND H. SINGH<sup>2</sup>**

*1. Department of Biotechnology, RKDF University, Bhopal.*

*2. People's Medical College and Research Centre, Bhopal.*

### ABSTRACT

The genetic haemotological disorder such as beta-thalassaemia and sickle cell anaemia is one of the burning problems in India. The community wise study is of great help as it provides versatile information. A random cross-sectional study was conducted in 500 volunteers of Sindhi community belonging to all age groups and both sexes. The mass screening was done by help of NESTROFT, Sickling, Solubility and complete blood picture were performed on all samples along with BMI. Those positive for either one or both, screening tests were further analyzed for HbA<sub>2</sub> by HPLC D-10. 120 positive cases of haemoglobinopathies were further analyzed for copper /zinc ratio. 120 positive cases of haemoglobinopathies were having low level of zinc and high level of copper, the ratio of copper / zinc was high along with low BMI. The positive cases were having different clinical manifestations along with liver and heart diseases in some cases.

**KEYWORDS:** Beta-Thalassaemia, Sickle Cell Anaemia, NESTROFT, Sickling, Solubility, Copper /Zinc Ratio



**M. KAUR**

Department of Biotechnology, RKDF University, Bhopal, India

## INTRODUCTION

Haemoglobinopathies are genetic disorder of the structure and function of haemoglobin and are of great public health concern<sup>1</sup>. Haemoglobinopathies include structural variants of haemoglobin such as sickle haemoglobin (HbS) and disorders in which the synthesis of one or more globin molecules is reduced or absent (the thalassaemias)<sup>2-4</sup>. The term thalassaemia is derived from the Greek, thalassa (sea) and haima (blood)<sup>5</sup>. It is prevalent across the world due to migration<sup>6</sup>. Alpha-thalassaemia is a common hereditary condition caused by deletions or point mutations in one or both alpha-globin genes, located on chromosome 16<sup>7-8</sup>. Beta -thalassaemia is caused by more than 200 point mutations in the  $\beta$ - globin genes on chromosome 11<sup>9</sup> resulting in absent or decreased synthesis of  $\beta$ - globin chains causing imbalance between  $\alpha$ - and  $\beta$ -chains and ensuing ineffective erythropoiesis, hemolysis and anaemia<sup>10-12</sup>. Sickle cell anemia results from point mutation in one of the amino acids forming globin chain of hemoglobin by the substitution of a hydrophilic moiety (Glutamic acid), negatively charged by a hydrophobic amino acid (Valine), and cause neutral charge at the sixth position of  $\beta$ -chain of hemoglobin molecule. Unlike normal haemoglobin sickle haemoglobin has net positive charge which results in reduce solubility. Upon deoxygenation in microcirculation sickle haemoglobin molecule reversibly aggregates into paracrystalline polymers, which forms long fiber bundle and distort erythrocytes giving characteristics distorted sickled shapes RBC's<sup>13-17</sup>.

### Trace Elements

Trace elements play a pivotal role in the human body and participate in various bio-chemical reactions. Zinc is the abundant intracellular element with 85% of total zinc found in muscles and bone where as 0.1 % in the plasma<sup>18</sup>. It forms structural part of more than 300 metalloenzymes like super oxide dismutase<sup>19</sup>. Plays an essential role in human growth, development<sup>20</sup> acts as an antioxidant,<sup>21-22</sup>

synthesis, storage and secretion of insulin,<sup>23-24</sup> host defense mechanisms<sup>25-28</sup> and in thyroid metabolism, its deficiency causes reduction in concentration of T3 in plasma<sup>29-30</sup>. Impaired growth, alopecia, loss of weight are few complications due to zinc deficiency, which is one of the factors responsible for growth and puberty disorders in thalassemic patients<sup>31</sup>. Copper is an essential structural element of many enzymes acting as cofactor in enzymatic reactions like those of cytochrome C, Lysyl oxidase, superoxide dismutase<sup>32-33</sup>. It helps in growth and proliferation of healthy cells, lymphocytes maturation and regulates the immune function<sup>34</sup>. It maintains the elasticity of the skin, blood vessels, and lungs and has antioxidant, antibacterial property.

## MATERIALS AND METHODS

The study was conducted to screen the haemoglobinopathies in Sindhi community living in Bhopal, Madhya Pradesh (MP). In this prospective cross sectional study 500 subjects (300 males and 200 females) between age group from 1 to 50 years were examined.

### i. Physical Examination

The family history, related complications of diseases, physical examination, height and weight were ascertained by physician.

### ii. Sample Collection

5 ml of venous blood was drawn from the cubital vein using disposable needle and syringes after having written consent of the patients. Blood sample was divided into two parts (1) one part in EDTA vial for hematological and HbA2 analysis (2) one in plain vial for collecting the serum.

### iii. NESTROFT<sup>35-36</sup>

The mass screening was done with the help of NESTROFT. 2 ml of 0.36% buffered saline solution and 2 ml distilled water was taken in tube. A drop of blood was added to each tube and left undisturbed for 1/2 an hour at room temperature. The samples were examined using light against the background of black

lines. The results were interpreted as positive when the black lines were not visible. A positive test indicates lowered red cell osmotic fragility, suggestive of thalassemia trait.

#### iv. Sickling test <sup>37</sup>

Twenty micro liters of each blood sample, was mixed with 20 micro liters of 2% sodium metabisulphite on a cover slip. A slide was then gently pressed onto the cover slip and the cover-slip was ringed with candle wax. The slide preparations were left in a humidified chamber for 15 minutes at room temperature and then examined under the microscope (x10). Further observations were taken after 30 minutes, 1 and 2 hours interval. Sickling was considered to be positive when more than 25% of the red blood cells were sickled.

#### v. Solubility Test <sup>37</sup>

Twenty micro-liters of each sample were mixed with 2 ml of 0.02% sodium dithionate in a test tube and left to stand at room temperature for 5

minutes. The samples were examined using light against the background of black lines. The results were interpreted as positive when the black lines were not visible.

#### vi. Blood Analysis <sup>38</sup>:

The complete blood picture was analyzed by Automated Haematology Analyzer. The EDTA blood samples were used.

#### vii. HbElectrophoresis <sup>39</sup>:

The NESTROFT and Solubility positive samples were analyzed for haemoglobinopathies (thalassaemia & sickle cell disease) by help of HPLC D-10.

#### viii. Copper / Zinc measurement <sup>40-41</sup>

The level of copper and zinc were assessed in subjects having haemoglobinopathies with the help of atomic absorption spectrophotometer (SHIMADZU Model AA-6300), used in accordance with the manufacturer's operating manual.

## FINDINGS

According to the study 140 out of 500 subjects were NESTROFT & solubility test positive. 140 positive subjects were taken for further study. The table 1 and 2 depicts the breakup of sample according to the gender and diagnosis of various haemoglobinopathies.

**Table No. 1**  
**Showing the distribution of the samples according to the gender**

| Variables | Number | Percentage | Cumulative Percentage |
|-----------|--------|------------|-----------------------|
| Male      | 88     | 73.33      | 73.33                 |
| Female    | 32     | 26.67      | 100                   |

**Table No. 2**  
**Depicting the distribution of the samples according to the diagnosis in 120 subjects**

| Variables                                   | Number of subjects | Percentage | Cumulative Percentage |
|---|--------------------|------------|-----------------------|
| $\beta$ -thalassaemia minor                 | 77                 | 64.16      | 64.16                 |
| $\beta$ -thalassaemia major                 | 14                 | 11.66      | 75.82                 |
| Sickle beta-thalassaemia( Hb S/ $\beta$ Th) | 16                 | 13.33      | 89.15                 |
| Sickle cell trait (hgb AS)                  | 9                  | 7.50       | 96.65                 |
| Sickle cell Disease (SCD)                   | 3                  | 2.50       | 99.15                 |
| Hemoglobin E (HbE)                          | 1                  | .85        | 100                   |

The table 3 representing the values of chromatogram and haematogram of all the 120 subjects having different haemoglobinopathies. The figure No.1 represents the haematograms and chromatogram of the patients having haemoglobinopathies.

**Table No. 3**  
**Depicting the Values of Chromatogram & Haematogram Readings of Subject of Haemoglobinopathies.**

| No.Subject | A <sub>0</sub> | F   | A <sub>2</sub> | S.W. | RBC  | Hb   | MCV  | MCH  | MCHC  | RDW   | Findings             |
|------------|----------------|-----|----------------|------|------|------|------|------|-------|-------|----------------------|
| T-1        | 82.6           | >1  | 7.7            | -    | 6.69 | 13.8 | 68.6 | 20.7 | 27.1  | 18.2  | β-thalassaemia minor |
| T-2        | 83.6           | >1  | 5.6            | -    | 6.06 | 11.9 | 65.1 | 19.6 | 30.1  | 17.4  | β-thalassaemia minor |
| T-3        | 79.2           | >1  | 6.3            | 2.0  | 5.0  | 10.2 | 57.1 | 24.7 | 25.2  | 16.02 | β-thalassaemia minor |
| T-4        | 86.2           | >1  | 4.2            | -    | 4.5  | 9.1  | 61.0 | 28.4 | 19.02 | 14.3  | β-thalassaemia minor |
| T-5        | 65.8           | >1  | 6.3            | -    | 4.17 | 9.2  | 66.7 | 22.1 | 33.1  | 26.2  | β-thalassaemia minor |
| T-6        | 68.5           | >1  | 5.8            | -    | 3.9  | 8.0  | 65.4 | 18.8 | 31.0  | 32.4  | β-thalassaemia minor |
| T-7        | 79.7           | >1  | 4.2            | 3.0  | 3.31 | 6.6  | 86.1 | 28.7 | 33.3  | 51.3  | β-thalassaemia minor |
| T-8        | 79.4           | >1  | 9.9            | -    | 5.44 | 10.2 | 61.8 | 18.8 | 30.4  | 36.2  | β-thalassaemia minor |
| T-9        | 84.8           | >1  | 4.2            | -    | 4.9  | 8.8  | 65.4 | 17.9 | 27.4  | 45.0  | β-thalassaemia minor |
| T-10       | 84.4           | >1  | 5.4            | -    | 5.33 | 16.3 | 88.0 | 30.6 | 34.8  | 44.0  | β-thalassaemia minor |
| T-11       | 82.3           | >1  | 5.9            | -    | 4.72 | 7.4  | 57.2 | 15.7 | 27.4  | 41.7  | β-thalassaemia minor |
| T-12       | 83.5           | >1  | 6.5            | -    | 4.89 | 7.5  | 56.0 | 15.3 | 27.4  | 46.7  | β-thalassaemia minor |
| T-13       | 61.3           | >1  | 3.7            | 2.0  | 4.50 | 6.9  | 58.0 | 15.3 | 26.4  | 41.4  | β-thalassaemia minor |
| T-14       | 10.0           | >1  | 5.4            | 60.4 | 5.51 | 13.6 | 76.0 | 24.7 | 32.5  | 40.2  | Hb S/β Th            |
| T-15       | 60.0           | >1  | 3.1            | 40   | 3.98 | 6.8  | 64.8 | 17.1 | 26.4  | 50.7  | hgb AS               |
| T-16       | 28.0           | 12  | 4.5            | 82   | 4.18 | 11.7 | 82.3 | 28.0 | 34.0  | 47.1  | Hb S/β Th            |
| T-17       | 81.2           | >1  | 8.8            | 1.0  | 5.71 | 10.2 | 59.4 | 17.9 | 30.1  | 34.5  | β-thalassaemia minor |
| T-18       | 80.8           | >1  | 5.4            | 2.0  | 5.37 | 9.6  | 60.5 | 17.9 | 29.5  | 35.9  | β-thalassaemia minor |
| T-19       | 11.0           | 9.0 | 5.9            | 52   | 6.59 | 11.5 | 59.2 | 17.5 | 29.5  | 37.5  | Hb S/β Th            |
| T-20       | 83.9           | >1  | 4.0            | 2.4  | 4.69 | 7.7  | 61.4 | 16.4 | 26.7  | 39.4  | β-thalassaemia minor |
| T-21       | 62.4           | >1  | 3.8            | 3.2  | 4.74 | 7.3  | 56.3 | 15.4 | 27.3  | 39.2  | β-thalassaemia minor |
| T-22       | 65.7           | >1  | 4.2            | 1.0  | 5.47 | 9.8  | 60.1 | 17.9 | 29.8  | 36.6  | β-thalassaemia minor |
| T-23       | 80             | 5.0 | 3.7            | 89.0 | 4.71 | 12.4 | 82.8 | 26.3 | 31.8  | 42.9  | Hb S/β Th            |
| T-24       | 18.0           | 10  | 3.9            | 59   | 3.94 | 12.2 | 89.6 | 31.0 | 34.6  | 47.0  | Hb S/β Th            |
| T-25       | 81.7           | >1  | 3.9            | 2.5  | 4.46 | 11.2 | 81.8 | 25.1 | 30.7  | 48.0  | β-thalassaemia minor |
| T-26       | 80.4           | >1  | 8.1            | 3.0  | 5.70 | 9.4  | 58.2 | 16.5 | 28.3  | 37.2  | β-thalassaemia minor |
| T-27       | 85.1           | >1  | 4.5            | 4.3  | 4.25 | 12.1 | 90.4 | 28.5 | 31.5  | 44.9  | β-thalassaemia minor |
| T-28       | 83.6           | >1  | 5.6            | -    | 6.06 | 11.9 | 65.1 | 19.6 | 30.1  | 17.4  | β-thalassaemia minor |
| T-29       | 79.2           | >1  | 6.3            | -    | 5.0  | 10.2 | 57.1 | 24.7 | 25.2  | 16.2  | β-thalassaemia       |

|      |      |      |     |      |      |      |      |      |       |      |                          |
|------|------|------|-----|------|------|------|------|------|-------|------|--------------------------|
| T-30 | 86.2 | >1   | 4.2 | -    | 4.5  | 9.01 | 61.0 | 28.4 | 19.02 | 14.3 | minor<br>β-thalassaemia  |
| T-31 | 82.3 | >1   | 5.9 | -    | 4.72 | 7.4  | 57.2 | 15.7 | 27.4  | 41.7 | minor<br>β-thalassaemia  |
| T-32 | 65.0 | 11   | 3.4 | 38   | 4.18 | 11.7 | 82.3 | 28.5 | 34.1  | 47.1 | hgb AS                   |
| T-33 | 82.7 | >1   | 5.9 | -    | 4.61 | 7.0  | 57.4 | 15.3 | 28.4  | 40.5 | β-thalassaemia           |
| T-34 | 82.3 | >1   | 5.9 | -    | 4.72 | 7.4  | 57.2 | 15.7 | 27.4  | 41.7 | minor<br>β-thalassaemia  |
| T-35 | 83.5 | >1   | 6.5 | -    | 4.89 | 7.5  | 56.0 | 15.3 | 27.4  | 46.7 | β-thalassaemia           |
| T-36 | 54.0 | 21   | 3.3 | 39   | 4.71 | 12.4 | 82.8 | 26.3 | 31.8  | 42.9 | minor<br>hgb AS          |
| T-37 | 0.0  | 21   | 3.8 | 92   | 3.94 | 12.2 | 89.6 | 31.0 | 34.6  | 47.0 | Hb S/β Th                |
| T-38 | 78   | >1   | 3.2 | 2.3  | 4.69 | 3.2  | 61.4 | 16.4 | 26.7  | 39.4 | β-thalassaemia           |
| T-39 | 86.2 | >1   | 4.4 | -    | 4.5  | 9.1  | 61.0 | 28.0 | 19.02 | 14.3 | major<br>β-thalassaemia  |
| T-40 | 65.8 | >1   | 6.5 | -    | 4.17 | 9.2  | 66.7 | 22.1 | 33.1  | 26.2 | β-thalassaemia           |
| T-41 | 65.7 | >1   | 3.6 | 1.0  | 5.47 | 9.8  | 60.1 | 17.9 | 29.8  | 36.6 | minor<br>β-thalassaemia  |
| T-42 | 80.9 | >1   | 3.1 | -    | 3.98 | 6.8  | 64.8 | 17.1 | 26.4  | 50.7 | major<br>β-thalassaemia  |
| T-43 | 0.0  | 9    | 3.7 | 89   | 4.18 | 11.7 | 82.3 | 28.0 | 34.0  | 47.1 | Hb S/β Th                |
| T-44 | 51.6 | >1   | 4.7 | 33.8 | 3.94 | 12.2 | 89.6 | 31.0 | 34.6  | 47.0 | Hb S/β Th                |
| T-45 | 85.1 | >1   | 4.5 | 4.3  | 4.25 | 12.1 | 90.4 | 28.5 | 31.5  | 44.9 | β -thalassaemia          |
| T-46 | 68.5 | >1   | 5.8 | -    | 3.9  | 8.0  | 65.4 | 18.8 | 31.0  | 32.4 | minor<br>β- thalassaemia |
| T-47 | 62.4 | >1   | 3.8 | 3.2  | 4.74 | 7.3  | 56.3 | 15.4 | 27.3  | 39.2 | β-thalassaemia           |
| T-48 | 58.4 | >1   | 6.0 | -    | 4.71 | 12.4 | 82.8 | 26.3 | 31.8  | 42.9 | major<br>β -thalassaemia |
| T-49 | 82.3 | >1   | 5.9 | -    | 4.72 | 7.4  | 57.2 | 15.7 | 27.4  | 41.7 | minor<br>β -thalassaemia |
| T-50 | 84.2 | >1   | 4.2 | -    | 4.9  | 8.8  | 65.4 | 17.9 | 27.4  | 45.0 | β -thalassaemia          |
| T-51 | 84.6 | >1   | 5.4 | -    | 5.33 | 16.3 | 88.0 | 30.6 | 34.8  | 44.0 | minor<br>β -thalassaemia |
| T-52 | 82.3 | >1   | 5.9 | -    | 4.72 | 7.4  | 57.2 | 15.7 | 27.4  | 41.7 | β -thalassaemia          |
| T-53 | 65.7 | >1   | 4.2 | 1.0  | 5.47 | 9.8  | 60.1 | 17.9 | 29.8  | 36.6 | minor<br>β -thalassaemia |
| T-54 | 0.0  | 22.0 | 4.7 | 83.0 | 4.71 | 12.4 | 82.8 | 26.3 | 31.8  | 42.9 | Hb S/β Th                |
| T-55 | 79.4 | >1   | 9.9 | -    | 5.44 | 10.2 | 61.8 | 18.8 | 30.4  | 36.2 | β -thalassaemia          |
| T-56 | 79.4 | >1   | 5.9 | 4.0  | 6.59 | 11.5 | 59.2 | 17.5 | 29.5  | 37.5 | minor<br>β -thalassaemia |
| T-57 | 80.2 | >1   | 5.5 | -    | 4.78 | 8.5  | 56.3 | 16.4 | 25.3  | 40.5 | β -thalassaemia          |
| T-58 | 82.3 | >1   | 5.9 | -    | 4.72 | 7.4  | 57.2 | 15.7 | 27.4  | 41.7 | minor<br>β -thalassaemia |
| T-59 | 5.3  | 12.0 | 3.7 | 49.0 | 4.18 | 11.7 | 82.3 | 28.5 | 34.1  | 47.1 | Hb S/β Th                |
| T-60 | 56.4 |      | 3.1 | 30.7 | 4.71 | 12.4 | 82.8 | 26.3 | 31.8  | 42.9 | hgb AS                   |
| T-61 | 61.3 | >1   | 3.7 | 2.0  | 4.50 | 6.9  | 58.0 | 15.3 | 26.4  | 41.4 | β-thalassaemia           |
| T-62 | 60.1 | 21   | 3.4 | 39.0 | 5.51 | 13.6 | 76.0 | 24.7 | 32.5  | 40.2 | major<br>hgb AS          |
| T-63 | 80.9 | >1   | 3.1 | 4.0  | 3.98 | 6.8  | 64.8 | 17.1 | 26.4  | 50.7 | β-thalassaemia           |

|      |      |      |     |      |      |      |      |      |       |      |                       |
|------|------|------|-----|------|------|------|------|------|-------|------|-----------------------|
|      |      |      |     |      |      |      |      |      |       |      | major                 |
| T-64 | 64.0 | 7.7  | 3.7 | 89.0 | 4.18 | 11.7 | 82.3 | 28.0 | 34.0  | 47.1 | Hb S/β Th             |
| T-65 | 81.2 | >1   | 8.8 | 1.0  | 5.71 | 10.2 | 59.4 | 17.9 | 30.1  | 34.5 | β -thalassaemia minor |
| T-66 | 80.8 | >1   | 5.4 | 2.0  | 5.37 | 9.6  | 60.5 | 17.9 | 29.5  | 35.9 | β -thalassaemia minor |
| T-67 | 79.4 | >1   | 5.9 | 4.0  | 6.59 | 11.5 | 59.2 | 17.5 | 29.5  | 37.5 | β -thalassaemia minor |
| T-68 | 83.9 | >1   | 4.0 | 2.4  | 4.69 | 7.7  | 61.4 | 16.4 | 26.7  | 39.4 | β -thalassaemia minor |
| T-69 | 61.3 | >1   | 3.7 | 2.0  | 4.50 | 6.9  | 58.0 | 15.3 | 26.4  | 41.4 | β-thalassaemia major  |
| T-70 | 0.0  | 24   | 3.9 | 78.0 | 5.51 | 13.6 | 76.0 | 24.7 | 32.5  | 40.2 | Hb S/β Th             |
| T-71 | 80.9 | >1   | 3.1 | 4.0  | 3.98 | 6.8  | 64.8 | 17.1 | 26.4  | 50.7 | β-thalassaemia major  |
| T-72 | 83.9 | >1   | 4.0 | 2.3  | 4.69 | 7.7  | 61.4 | 16.4 | 26.7  | 39.4 | β -thalassaemia minor |
| T-73 | 86.2 | >1   | 4.4 | -    | 4.5  | 9.1  | 61.0 | 28.0 | 19.02 | 14.3 | β-thalassaemia minor  |
| T-74 | 65.8 | >1   | 6.5 | -    | 4.17 | 9.2  | 66.7 | 22.1 | 33.1  | 26.2 | β -thalassaemia minor |
| T-75 | 65.7 | >1   | 4.2 | 1.0  | 5.47 | 9.8  | 60.1 | 17.9 | 29.8  | 36.6 | β -thalassaemia minor |
| T-76 | 80.9 | >1   | 3.1 | 4.0  | 3.98 | 6.8  | 64.8 | 17.1 | 26.4  | 50.7 | β-thalassaemia major  |
| T-77 | 0.0  | 12   | 3.2 | 91.0 | 4.18 | 11.7 | 82.3 | 28.0 | 34.0  | 47.1 | SCD                   |
| T-78 | 50.0 | <1   | 3.2 | 37.0 | 3.94 | 12.2 | 89.6 | 31.0 | 34.6  | 47.0 | hgb AS                |
| T-79 | 85.1 | >1   | 4.5 | 4.3  | 4.25 | 12.1 | 90.4 | 28.5 | 31.5  | 44.9 | β -thalassaemia minor |
| T-80 | 68.5 | >1   | 5.8 | -    | 3.9  | 8.0  | 65.4 | 18.8 | 31.0  | 32.4 | β -thalassaemia minor |
| T-81 | 62.4 | >1   | 3.8 | 3.2  | 4.74 | 7.3  | 56.3 | 15.4 | 27.3  | 39.2 | β -thalassaemia major |
| T-82 | 65.7 | >1   | 4.2 | 1.0  | 5.47 | 9.8  | 60.1 | 17.9 | 29.8  | 36.6 | β -thalassaemia minor |
| T-83 | 51.0 | <1   | 3.2 | 43.0 | 4.71 | 12.4 | 82.8 | 26.3 | 31.8  | 42.9 | hgb AS                |
| T-84 | 3.9  | 18.0 | 4.1 | 78.0 | 3.94 | 12.2 | 89.6 | 31.0 | 34.6  | 47.0 | Hb S/β Th             |
| T-85 | 81.7 | >1   | 3.9 | 2.5  | 4.46 | 11.2 | 81.8 | 25.1 | 30.7  | 48.0 | β -thalassaemia minor |
| T-86 | 80.4 | >1   | 8.1 | 3.0  | 5.70 | 9.4  | 58.2 | 16.5 | 28.3  | 37.2 | β -thalassaemia minor |
| T-87 | 85.1 | >1   | 4.5 | 4.3  | 4.25 | 12.1 | 90.4 | 28.5 | 31.5  | 44.9 | β -thalassaemia minor |
| T-88 | 83.6 | >1   | 5.6 | -    | 6.06 | 11.9 | 65.1 | 19.6 | 30.1  | 17.4 | β -thalassaemia minor |
| T-89 | 79.2 | >1   | 6.3 | -    | 5.0  | 10.2 | 57.1 | 24.7 | 25.2  | 16.2 | β -thalassaemia minor |
| T-90 | 86.2 | >1   | 4.2 | -    | 4.5  | 9.01 | 61.0 | 28.4 | 19.02 | 14.3 | β -thalassaemia minor |
| T-91 | 82.3 | >1   | 5.9 | -    | 4.72 | 7.4  | 57.2 | 15.7 | 27.4  | 41.7 | β -thalassaemia minor |
| T-92 | 22.0 | 12.0 | 35  | 63.0 | 4.18 | 11.7 | 82.3 | 28.5 | 34.1  | 47.1 | Hb S/β Th             |
| T-93 | 82.7 | >1   | 5.9 | -    | 4.61 | 7.0  | 57.4 | 15.3 | 28.4  | 40.5 | β -thalassaemia minor |
| T-94 | 82.3 | >1   | 5.9 | -    | 4.72 | 7.4  | 57.2 | 15.7 | 27.4  | 41.7 | β -thalassaemia minor |
| T-95 | 83.5 | >1   | 6.5 | -    | 4.89 | 7.5  | 56.0 | 15.3 | 27.4  | 46.7 | β -thalassaemia minor |
| T-96 | 0.0  | 13.0 | 4.2 | 91.0 | 4.71 | 12.4 | 82.8 | 26.3 | 31.8  | 42.9 | Hb S/β Th             |
| T-97 | 59.0 | <1   | 3.3 | 43.0 | 3.94 | 12.2 | 89.6 | 31.0 | 34.6  | 47.0 | hgb AS                |

|       |      |      |      |      |      |      |      |      |       |      |                       |
|-------|------|------|------|------|------|------|------|------|-------|------|-----------------------|
| T-98  | 83.9 | >1   | 4.0  | 2.3  | 4.69 | 7.7  | 61.4 | 16.4 | 26.7  | 39.4 | β -thalassaemia minor |
| T-99  | 86.2 | >1   | 4.4  | -    | 4.5  | 9.1  | 61.0 | 28.0 | 19.02 | 14.3 | β -thalassaemia minor |
| T-100 | 65.8 | >1   | 6.5  | -    | 4.17 | 9.2  | 66.7 | 22.1 | 33.1  | 26.2 | β -thalassaemia minor |
| T-101 | 65.7 | >1   | 4.2  | 1.0  | 5.47 | 9.8  | 60.1 | 17.9 | 29.8  | 36.6 | β -thalassaemia minor |
| T-102 | 80.9 | >1   | 3.1  | 4.0  | 3.98 | 6.8  | 64.8 | 17.1 | 26.4  | 50.7 | β -thalassaemia minor |
| T-103 | 30.0 | 18   | 4.5  | 55.0 | 4.18 | 11.7 | 82.3 | 28.0 | 34.0  | 47.1 | Hb S/β Th             |
| T-104 | 0.0  | 100  | 3.2  | 44.0 | 3.94 | 12.2 | 89.6 | 31.0 | 34.6  | 47.0 | SCD                   |
| T-105 | 85.1 | >1   | 4.5  | 4.3  | 4.25 | 12.1 | 90.4 | 28.5 | 31.5  | 44.9 | β -thalassaemia minor |
| T-106 | 68.5 | >1   | 5.8  | -    | 3.9  | 8.0  | 65.4 | 18.8 | 31.0  | 32.4 | β -thalassaemia minor |
| T-107 | 62.4 | >1   | 3.8  | 3.2  | 4.74 | 7.3  | 56.3 | 15.4 | 27.3  | 39.2 | β -thalassaemia major |
| T-108 | 58.4 | >1   | 6.0  | -    | 4.71 | 12.4 | 82.8 | 26.3 | 31.8  | 42.9 | β -thalassaemia minor |
| T-109 | 82.3 | >1   | 5.9  | -    | 4.72 | 7.4  | 57.2 | 15.7 | 27.4  | 41.7 | β -thalassaemia minor |
| T-110 | 84.2 | >1   | 4.2  | -    | 4.9  | 8.8  | 65.4 | 17.9 | 27.4  | 45.0 | β -thalassaemia minor |
| T-111 | 84.6 | >1   | 5.4  | -    | 5.33 | 16.3 | 88.0 | 30.6 | 34.8  | 44.0 | β -thalassaemia minor |
| T-112 | 82.3 | >1   | 5.9  | -    | 4.72 | 7.4  | 57.2 | 15.7 | 27.4  | 41.7 | β -thalassaemia minor |
| T-113 | 65.7 | >1   | 4.2  | 1.0  | 5.47 | 9.8  | 60.1 | 17.9 | 29.8  | 36.6 | β -thalassaemia minor |
| T-114 | 57.0 | <1   | 4.3  | 91.0 | 4.71 | 12.4 | 82.8 | 26.3 | 31.8  | 42.9 | hgb AS                |
| T-115 | 79.4 | >1   | 12.9 | -    | 5.44 | 10.2 | 61.8 | 18.8 | 30.4  | 36.2 | HbE                   |
| T-116 | 79.4 | >1   | 5.9  | 4.0  | 6.59 | 11.5 | 59.2 | 17.5 | 29.5  | 37.5 | β -thalassaemia major |
| T-117 | 86.2 | >1   | 3.2  | -    | 4.5  | 9.1  | 61.0 | 28.4 | 19.02 | 14.3 | β -thalassaemia major |
| T-118 | 79.7 | >1   | 2.2  | 3.0  | 3.31 | 6.6  | 86.1 | 28.7 | 33.3  | 51.3 | β -thalassaemia major |
| T-119 | 0.0  | 6.2  | 4.3  | 91.0 | 4.18 | 11.7 | 82.3 | 28.5 | 34.1  | 47.1 | Hb S/β Th             |
| T-120 | 0.0  | 13.0 | 3.1  | 92.0 | 4.71 | 12.4 | 82.8 | 26.3 | 31.8  | 42.9 | SCD                   |




Figure No. 1 Depicting the haematogram & Chromatogram of patients having Haemoglobinopathies

The Table-4 shows the frequency distribution of 84 subjects having different clinical manifestations at the time of examination and figure No.2 depicts the two subjects with clinical manifestations.

| <b>Table No.4</b>   |             |                |                   |                              |
|---|-------------|----------------|-------------------|------------------------------|
| <i>Showing the distribution of the subjects in the samples according presence or absence of some clinical manifestations.</i> |             |                |                   |                              |
| <b>Variables</b>  |             | <b>Numbers</b> | <b>Percentage</b> | <b>Cumulative percentage</b> |
| Weakness  | Present     | 84             | 70                | 70                           |
|   | Not Present | 36             | 30                | 100                          |
|   | Present     |                |                   |                              |
| Pale  | Present     | 98             | 82.1              | 82.1                         |
|   | Not Present | 22             | 17.1              | 100                          |
|   | Present     |                |                   |                              |
| Body ache   | Present     | 36             | 30                | 30                           |
|   | Not Present | 84             | 70                | 100                          |
|   | Present     |                |                   |                              |
| Jaundice  | Present     | 30             | 25                | 25                           |
|   | Not Present | 90             | 75                | 100                          |
|   | Present     |                |                   |                              |
| Bronze skin   | Present     | 54             | 45                | 45                           |
|   | Not Present | 66             | 55                | 100                          |
|   | Present     |                |                   |                              |
| Mongoloid Features  | Present     | 72             | 60.71             | 60.71                        |
|   | Not Present | 48             | 39.29             | 100                          |
|   | Present     |                |                   |                              |
| Liver enlargement   | Present     | 14             | 12.14             | 12.14                        |
|   | Not Present | 106            | 87.86             | 100                          |
|   | Present     |                |                   |                              |
| Spleen enlargement  | Present     | 18             | 15                | 15                           |
|   | Not Present | 102            | 85                | 100                          |
|   | Present     |                |                   |                              |
| Diabetes  | Present     | 7              | 6.42              | 6.42                         |
|   | Not Present | 113            | 93.58             | 100                          |
|   | Present     |                |                   |                              |
| Heart problem   | Present     | 6              | 5                 | 5                            |
|   | Not Present | 114            | 95                | 100                          |
|   | Present     |                |                   |                              |

Girl of 12 year with sickle cell anaemia

Boy of 10 year with Beta-thalassaemia



**Figure No.2**  
*shows the clinical manifestation of haemoglobinopathies:-*  
**Girl with sickle cell anaemia having vascularocclusion in right leg.**  
**Boy with beta-thalassaemia having discoloured skin and splenomegaly**

**The Table 5 shows the mean value height, weight and Body Mass Index BMI of subjects having haemoglobinopathies .**

**Table No. 5 shows the distribution of height , weight and BMI according to the type of haemoglobinopathies in the subjects.**

| Disease              | Height (in cm) | Weight (Kg) | BMI        |
|----------------------|----------------|-------------|------------|
| β-thalassaemia minor | 150±10         | 40±9        | 17.78±1.07 |
| β-thalassaemia major | 117.1±16       | 22±6.8      | 16.04±2.0  |
| Hb S/β Th            | 156±9          | 38±8.6      | 15.61±2.2  |
| Hgb AS               | 160±6          | 35±5.9      | 13.6±2.4   |
| SCD                  | 120±19         | 28±7.1      | 19.4±1.9   |
| HbE                  | 153±2          | 42±1        | 17.94±1.8  |

**Table 6 and 7 represents the frequency distribution of blood rate and chelation therapy in 33 patients.**

**Table No. 6 shows the frequency of blood transfusion given to 33 patients.**

| Frequency of blood transfusion | Number of patients | Percentage | Cumulative Percentage |
|--------------------------------|--------------------|------------|-----------------------|
| <2 weeks                       | 10                 | 30.30      | 30.30                 |
| 2-4 weeks                      | 12                 | 36.36      | 66.66                 |
| >4 weeks                       | 11                 | 33.34      | 100                   |

**Table No. 7 represents the treatment of chelators.**

| Frequency of iron chelator | Number of patients | Percentage | Cumulative Percentage |
|----------------------------|--------------------|------------|-----------------------|
| Desferol/Asunra            |                    |            |                       |
| <3 times/ weeks            | 9                  | 27.27      | 27.27                 |
| 3-4 times/ weeks           | 11                 | 33.33      | 60.60                 |
| >4 times /weeks            | 13                 | 39.40      | 100                   |

**The table-8 and 9 show the level of copper and zinc in 30 control 120 patients of different haemoglobinopathies.**

**Table No. 8 Showing the concentration of Copper (Cu) and Zinc (Zn) in control subjects.**

| Number of control | Copper (Cu) (µg/dl) | Zinc (Zn) (µg/dl) | Ratio (µg/dl) |
|-------------------|---------------------|-------------------|---------------|
| C1                | 101.75              | 96.44             | 1.05506       |
| C2                | 100.80              | 91.52             | 1.101399      |
| C3                | 90.45               | 84.23             | 1.073845      |
| C4                | 95.63               | 88.25             | 1.083626      |
| C5                | 87.18               | 80.97             | 1.076695      |
| C6                | 110.64              | 99.83             | 1.108284      |
| C7                | 103.42              | 96.73             | 1.069162      |
| C8                | 97.65               | 89.99             | 1.085121      |
| C9                | 92.71               | 85.98             | 1.078274      |
| C10               | 89.20               | 82.90             | 1.075995      |
| C11               | 101.75              | 96.44             | 1.05506       |
| C12               | 100.80              | 91.52             | 1.101399      |
| C13               | 90.45               | 84.23             | 1.073845      |
| C14               | 95.63               | 88.25             | 1.083626      |
| C15               | 87.18               | 80.97             | 1.076695      |
| C16               | 110.64              | 99.83             | 1.108284      |
| C17               | 103.42              | 96.73             | 1.069162      |
| C18               | 97.65               | 89.99             | 1.085121      |
| C19               | 92.71               | 85.98             | 1.078274      |

|     |        |       |          |
|-----|--------|-------|----------|
| C20 | 89.20  | 82.90 | 1.075995 |
| C21 | 101.75 | 96.44 | 1.05506  |
| C22 | 100.80 | 91.52 | 1.101399 |
| C23 | 90.45  | 84.23 | 1.073845 |
| C24 | 95.63  | 88.25 | 1.083626 |
| C25 | 87.18  | 80.97 | 1.076695 |
| C26 | 110.64 | 99.83 | 1.108284 |
| C27 | 103.42 | 96.73 | 1.069162 |
| C28 | 90.45  | 84.23 | 1.073845 |
| C29 | 95.63  | 88.25 | 1.083626 |
| C30 | 87.18  | 80.97 | 1.076695 |

The mean value of copper is 96.733 µg/dl ; zinc 89.503 µg/dl; ratio of copper / zinc 1.08057 in control.

**Table No. 9 Represents the values copper & Zinc in subjects with different haemoglobinopathies.**

| Number of subjects | Copper (Cu) (µg/dl) | Zinc (Zn) (µg/dl) | Ratio (µg/dl) |
|--------------------|---------------------|-------------------|---------------|
| T-1                | 162.10              | 38.65             | 4.194049      |
| T-2                | 155.20              | 36.97             | 4.197998      |
| T-3                | 157.70              | 37.89             | 4.162048      |
| T-4                | 167.43              | 40.19             | 4.165962      |
| T-5                | 170.46              | 41.09             | 4.148455      |
| T-6                | 164.33              | 39.51             | 4.1592        |
| T-7                | 151.19              | 36.17             | 4.179983      |
| T-8                | 161.65              | 38.91             | 4.154459      |
| T-9                | 160.33              | 39.10             | 4.100512      |
| T-10               | 158.49              | 37.87             | 4.185107      |
| T-11               | 165.52              | 40.11             | 4.126652      |
| T-12               | 153.49              | 36.91             | 4.158494      |
| T-13               | 162.50              | 39.40             | 4.124365      |
| T-14               | 158.95              | 38.33             | 4.146882      |
| T-15               | 154.66              | 37.32             | 4.144159      |
| T-16               | 169.35              | 40.67             | 4.164003      |
| T-17               | 173.42              | 41.90             | 4.138902      |
| T-18               | 166.54              | 39.88             | 4.176028      |
| T-19               | 159.89              | 38.17             | 4.188892      |
| T-20               | 167.48              | 40.06             | 4.180729      |
| T-21               | 153.65              | 37.01             | 4.151581      |
| T-22               | 173.40              | 42.30             | 4.099291      |
| T-23               | 159.35              | 38.70             | 4.117571      |
| T-24               | 161.88              | 39.10             | 4.140153      |
| T-25               | 158.44              | 38.30             | 4.136815      |
| T-26               | 160.99              | 38.77             | 4.152437      |
| T-27               | 171.94              | 41.59             | 4.134167      |
| T-28               | 168.63              | 40.49             | 4.164732      |
| T-29               | 157.29              | 37.96             | 4.143572      |
| T-30               | 170.81              | 41.08             | 4.157984      |
| T-31               | 156.59              | 37.89             | 4.132753      |
| T-32               | 164.82              | 40.05             | 4.115356      |
| T-33               | 159.61              | 38.44             | 4.152185      |
| T-34               | 155.60              | 37.33             | 4.168229      |
| T-35               | 163.48              | 39.67             | 4.120998      |
| T-36               | 159.95              | 38.87             | 4.114999      |
| T-37               | 165.30              | 40.17             | 4.115011      |
| T-38               | 164.80              | 39.45             | 4.17744       |
| T-39               | 172.65              | 41.94             | 4.116595      |
| T-40               | 173.68              | 42.14             | 4.1215        |
| T-41               | 164.26              | 39.49             | 4.159534      |
| T-42               | 157.34              | 38.03             | 4.13726       |
| T-43               | 161.28              | 38.75             | 4.162065      |

|       |        |       |          |
|-------|--------|-------|----------|
| T-44  | 157.69 | 38.15 | 4.133421 |
| T-45  | 170.89 | 41.29 | 4.138775 |
| T-46  | 174.54 | 42.25 | 4.131124 |
| T-47  | 168.94 | 40.63 | 4.158011 |
| T-48  | 159.98 | 38.91 | 4.111539 |
| T-49  | 163.75 | 39.81 | 4.113288 |
| T-50  | 165.76 | 40.35 | 4.108055 |
| T-51  | 156.10 | 37.42 | 4.171566 |
| T-52  | 148.66 | 35.44 | 4.194695 |
| T-53  | 149.65 | 36.17 | 4.137407 |
| T-54  | 153.10 | 37.10 | 4.126685 |
| T-55  | 160.38 | 39.05 | 4.107042 |
| T-56  | 164.94 | 39.84 | 4.14006  |
| T-57  | 159.35 | 38.48 | 4.141112 |
| T-58  | 169.19 | 40.93 | 4.133643 |
| T-59  | 157.87 | 38.47 | 4.103717 |
| T-60  | 165.37 | 40.27 | 4.106531 |
| T-61  | 156.59 | 37.89 | 4.132753 |
| T-62  | 164.82 | 40.05 | 4.115356 |
| T-63  | 159.61 | 38.44 | 4.152185 |
| T-64  | 155.60 | 37.33 | 4.168229 |
| T-65  | 163.48 | 39.67 | 4.120998 |
| T-66  | 159.95 | 38.87 | 4.114999 |
| T-67  | 165.30 | 40.17 | 4.115011 |
| T-68  | 164.80 | 39.45 | 4.17744  |
| T-69  | 172.65 | 41.94 | 4.116595 |
| T-70  | 173.68 | 42.14 | 4.1215   |
| T-71  | 164.26 | 39.49 | 4.159534 |
| T-72  | 157.34 | 38.03 | 4.13726  |
| T-73  | 161.28 | 38.75 | 4.162065 |
| T-74  | 157.69 | 38.15 | 4.133421 |
| T-75  | 162.10 | 38.65 | 4.194049 |
| T-76  | 155.20 | 36.97 | 4.197998 |
| T-77  | 157.70 | 37.89 | 4.162048 |
| T-78  | 167.43 | 40.19 | 4.165962 |
| T-79  | 170.46 | 41.09 | 4.148455 |
| T-80  | 164.33 | 39.51 | 4.1592   |
| T-81  | 151.19 | 36.17 | 4.179983 |
| T-82  | 161.65 | 38.91 | 4.154459 |
| T-83  | 160.33 | 39.10 | 4.100512 |
| T-84  | 158.49 | 37.87 | 4.185107 |
| T-85  | 165.52 | 40.11 | 4.126652 |
| T-86  | 153.49 | 36.91 | 4.158494 |
| T-87  | 162.50 | 39.40 | 4.124365 |
| T-88  | 154.66 | 37.32 | 4.144159 |
| T-89  | 169.35 | 40.67 | 4.164003 |
| T-90  | 173.42 | 41.90 | 4.138902 |
| T-91  | 166.54 | 39.88 | 4.176028 |
| T-92  | 159.89 | 38.17 | 4.188892 |
| T-93  | 167.48 | 40.06 | 4.180729 |
| T-94  | 153.65 | 37.01 | 4.151581 |
| T-95  | 173.40 | 42.30 | 4.099291 |
| T-96  | 159.35 | 38.70 | 4.117571 |
| T-97  | 161.88 | 39.10 | 4.140153 |
| T-98  | 158.44 | 38.30 | 4.136815 |
| T-99  | 160.99 | 38.77 | 4.152437 |
| T-100 | 171.94 | 41.59 | 4.134167 |
| T-101 | 168.63 | 40.49 | 4.164732 |
| T-102 | 161.28 | 38.75 | 4.162065 |
| T-103 | 157.69 | 38.15 | 4.133421 |
| T-104 | 170.89 | 41.29 | 4.138775 |
| T-105 | 174.54 | 42.25 | 4.131124 |

|  |        |       |          |
|--|--------|-------|----------|
| T-106  | 168.94 | 40.63 | 4.158011 |
| T-107  | 159.98 | 38.91 | 4.111539 |
| T-108  | 161.28 | 38.75 | 4.162065 |
| T-109  | 157.69 | 38.15 | 4.133421 |
| T-110  | 162.10 | 38.65 | 4.194049 |
| T-111  | 155.20 | 36.97 | 4.197998 |
| T-112  | 157.70 | 37.89 | 4.162048 |
| T-113  | 167.43 | 40.19 | 4.165962 |
| T-114  | 170.46 | 41.09 | 4.148455 |
| T-115  | 164.33 | 39.51 | 4.1592   |
| T-116  | 151.19 | 36.17 | 4.179983 |
| T-117  | 161.65 | 38.91 | 4.154459 |
| T-118  | 160.33 | 39.10 | 4.100512 |
| T-119  | 158.49 | 37.87 | 4.185107 |
| T-120  | 165.52 | 40.11 | 4.126652 |
| The mean value of copper is 162.469 (µg/dl) ; zinc is 39.182 (µg/dl);<br>Ratio of copper / zinc is 4.1468 (µg/dl). |        |       |          |

## DISCUSSION

The present study was conducted in 500 volunteers of Sindhi community, out of which 140 NESTROFT and solubility test positive samples were further analyzed with the help of HPLC D-10 for different types of haemoglobinopathies. 120 subjects were having haemoglobinopathies (thalassaemia and sickle cell anaemia or combination of thalassaemia/sickle cell anaemia. Haemoglobinopathies (sickle & thalassaemia) were seen in Sindhi community, this may be due to high rate of consanguineous marriage<sup>42</sup>. The gender discrimination is seen in this study since the number of male subjects 88 (73.33%) constituted higher than females 32 (26.67%), This could be explained by the fact that people in developing countries are more concerned about male than female children. Since men are basically considered as bread earner in developing countries. The mean value of Hb was 9.88 gm/dl, Total RBC Count 4.75 mill/cumn, MCV 68.89 fL, MCH 21.80 pg, MCHC 29.42 g/ dl and RDW 38.63 % that shows that RBC, Hb, MCV, MCH, MCHC were lower as compared to control where as RDW was higher. It is in agreement with other studies conducted on these parameters<sup>43-44</sup>. The BMI in the present study was low as compared to standard. In the case of beta-thalassaemia minor the height, weight and BMI were 150±10, 40±9, 17.78±1.07; β-thalassaemia major 117.1±16, 22±6.8, 16.04±2.0; HbS/βTh

156±9, 38±8.6, 15.61±2.2 ; Hb AS 160±6, 35±5.9, 13.6±2.4; SCD 120±19, 28±7.1, 19.4±1.9; HbE 153±2, 42±1, 17.94±1.8. The present sample shows that subjects with haemoglobinopathies were underweight and having growth retardation these findings co-inside with the other studies<sup>19, 45-46</sup>.

The clinical findings like paleness, weakness, body ache, spleen enlargement and liver enlargement in the samples indicate that subjects were under poor treatments due to low socio-economic condition and they were highly prone to infections<sup>2</sup>. These clinical complications are more related to zinc and copper as documented in many studies<sup>47-50</sup>. Six patients were suffering from heart diseases in the sample group, It is documented that excess of iron is deposited in the human body due to blood transfusion and not removed thus lead to death due to iron over loading of myocardium<sup>51-52</sup>. In a study it was found that patients with thalassaemia major showed marked reduction in contractile state and milder left Ventricle Function (LVF) than in thalassaemia intermedia. It is important to notice that classical changes of untreated thalassaemia major are now regularly seen only in countries without resources to support long term transfusion programs<sup>53-54</sup>. The study shows higher level of copper / zinc ratio 4.1468 (µg/dl) in 120 patients of haemoglobinopathies where as in 30 control it is copper / zinc

1.08057( $\mu\text{g}/\text{dl}$ ). It shows lower level of zinc as compare to copper in haemoglobinopathies. The similar observation were observed by <sup>42,48,55-61</sup>. The growth retardation, puberty disorder, dysgeusia and clinical manifestation were observed in the samples (thalassaemics & sickle cell anaemia) mainly due to low level of zinc the similar observation observed by <sup>62-76</sup>. The chelation therapy has many complications like growth impairment, endocrinopathy, hypogonadism etc <sup>77-78</sup>. Desferrioxamine (DFO) the chelator affects the plasma level of zinc and copper and cobalt <sup>30,79-81</sup>. These elements are more likely to be chelated in presence of reduced iron level <sup>82</sup>. Increased glomerular filtration rate of Zn is responsible for hyperzincuria resulted from hemolysis of red blood cells <sup>23, 42, 50, 64, 71, 83-89</sup>.

It has been reported in experimental study that plasma somatomedin-c correlates with zinc status in animal and activity of somatomedin-C decreases as a result of dietary zinc deficiency <sup>56,90-91</sup>. Zinc supplementation has shown positive effect on the hepatic synthesis of somatomedin-C <sup>92-94</sup>. It has been shown in many studies that zinc deficiencies are allied with thalassaemia <sup>40,41,64,80,83,90,95-97</sup>, may be due to reduced zinc intake and chelation therapy <sup>42,80,87,90,98-104</sup>. Zinc deficiency plays important role in the growth retardation and sexual development in thalassaemic <sup>31</sup>. The close relation between serum Cu and iron can be explained by the importance of copper containing enzymes and co-factors for iron absorption and the effect of copper on the release of iron from the body stores as well the utilization of iron in haemoglobin synthesis <sup>105-106</sup>. Hypercupraemia is seen in haemochromatosis the principle complication in thalassaemia <sup>44-107</sup>. According to some studies zinc and copper level are shown higher in haemoglobinopathies (thalassaemics & Sickle cell anaemia <sup>108-109</sup>), which may be due to blood transfusion from healthy donor <sup>110</sup> or due to cirrhotic changes owing to

hemosiderosis or because of abnormal rate of glomerular filtration of zinc seen in chronic hemolysis <sup>111</sup> and may be due to impaired zinc and copper utilization in tissue in the pathogenesis <sup>91</sup>. Wide range of discrepancies were observed in various reports these different findings may be due to variation in subject age, different transfusion and chelators therapies <sup>112</sup>, or due to anorexia, nutritional status, psychological problems and different metabolic and endocrine complications <sup>113-114</sup>. Zinc concentration is higher in RBC <sup>64</sup>. During transfusion of blood a considerable proportion of transfused cells are destroyed <sup>43</sup>, patients who are transfusion dependent will have higher serum zinc as compared to control subjects. Liver is storage organ for zinc <sup>115</sup>, due to iron overload; oxygen free radical may induce peroxidative damage <sup>116</sup>, thus increased serum zinc from damaged hepatocytes <sup>115</sup>. It was hypothesis that variation of serum zinc level may be due to leukocyte endogenous mediator (LEM) which has the property of mobilizing zinc from its stores in liver and other tissue to the serum <sup>117</sup>.

## CONCLUSION

This study reveals that zinc deficiency is common in haemoglobinopathic patients (thalassaemia and sickle cell anaemia) but there is no copper deficiency. It was observed that about 24% of Shindhi community is suffering from haemoglobinopathies. It is observed low zinc level in haemoglobinopathy is one of the factor causing growth retardation and other complication like diabetes, liver disorder and heart diseases. With dietary intake of zinc and transfusion of healthy blood will reduce these complications. It is suggested that measurement of serum zinc/ copper levels be a routine part of management of all patients of haemoglobinopathies particularly those who are treated by chelation therapy.

## REFERENCE

1. Driss A., Asare K.O., Hibbert J.M., Gee B.E., Adamkiewicz T.V., Stiles J.K.: Sickle Cell Disease in the Post Genomic Era: A Monogenic Disease with a Polygenic Phenotype. *Genomics Insights*, 2009(2):23-48, (2009) PMID: 20401335.
2. Weatherall D.J.: The thalassaemias. *British Medical Journal*, 314(7095): 1675–1678, (1997). PMID: 9193293.
3. Weatherall D.J., Clegg J.B.: The thalassaemia syndromes (4th ed), Blackwell scientific.2001. ISBN-10:0865426643; ISBN-13: 978-0865426641.
4. Sinha S., Black M.L., Agarwal S., Colah R., Das R., Ryan K., Bellgard M., Bittles A.H.: Profiling  $\beta$ -thalassaemia mutations in India at state and regional levels: implications for genetic education, screening and counselling programmes. *Hugo J.*, 3(1-4): 51–62. (2009) PMID: 21119755.
5. Thein S.L.: Genetic insights into the clinical diversity of beta thalassaemia. *Br J Haematol.* ,124(3):264-74, (2004) PMID: 14717773.
6. Herklotz R., Risch L., Huber A.R.: Hemoglobinopathies--clinical symptoms and diagnosis of thalassaemia and abnormal hemoglobins]. *Ther Umsch.* , 63(1):35-46, (2006). PMID:16450733
7. Higgs D.R., Weatherall D.J.: The alpha thalassaemias. *Cell Mol Life Sci.*, 66(7):1154-1162, 2009 PMID: 19020805.
8. Fucharoen S., Winichagoon P.: Haemoglobinopathies in Southeast Asia. *Indian J Med Res.* 134:498-506,( 2011). PMID: 22089614.
9. Raja JV, Rachchh MA, Gokani RH. Recent advances in gene therapy for thalassaemia. *J Pharm Bioallied Sci.*, 4(3):194-201, (2012). PMID: 22923960.
10. Schrier S.L.: Pathobiology of thalassaemic erythrocytes. *Curr Opin Hematol.*, 4(2):75-8. (1997). PMID: 9107522.
11. Olivieri N.: The b-thalassemyias. *N Engl J Med.*.,341(2):99-109, (1999). PMID: 10395635.
12. Leung T.N., Lau T.K., Chung T.K.H.: Thalassaemia screening in pregnancy. *Curr Opin Obstet Gynecol.*, 17(2):129-34 (2005). PMID: 15758603.
13. Denise, M. Harmening : Hemolytic anemia: Intra-corporcular defects. In *Clinical Hematology and Fundamentals of Hemostasis*, (2nd edition), Publishers, F.A.Davis Company, Philadelphia, 142-162, (1992). ISBN: 9780803617322.
14. McGaw L.J., Jager A.K., van Staden J.:Antibacterial anthelmintic and antiamebic activity in south African medicinal plants. *J Ethnopharmacol.*, 72(1-2):247-63,( 2000) . PMID: 10967478.
15. Kambizi L., Afolayan A.J.: An ethnobotanical study of plants used for the treatment of sexually transmitted diseases (njovhera) in Guruve District, Zimbabwe. *J Ethnopharmacol.*, 77(1):5-9, (2001). PMID: 11483371.
16. Mehanna, A.S.: Sickle cell anemia and antisickling agent then and now. *Curr Med Chem.*, 8(2):79-88,(2001). PMID: 11172667.
17. Firth P.G, Head C.A. Sickle cell disease and anesthesia. *Anesthesiology.* 2004; 101(3):766-85. PMID: 15329603.
18. King J.C., Shames D.M., and Woodhouse L.R.: Zinc homeostasis in humans. *J Nutr.* 2000; 130(5S (I)):1360S-6S. PMID: 10801944.
19. Mohammadreza Rashidi, Maryam Aboomardani, Maryam Rafrat, Seyed-Rafie Arefhosseini, Abbasali Keshtkar, and Hamidreza: Effects of Vitamin E and Zinc Supplementation on Antioxidants in Beta thalassaemia major Patients. *Iranian Journal of Pediatrics*, 21 (1): 8-14 ,( 2011).
20. Mahyar A. The preventive role of zinc from communicable and noncommunicable

- diseases in children. *NCD Malaysia*, 4(2):21-6 (2005).
21. Reily C.: *The nutritional trace metals*, 2nd ed. India: Black Well Publication. 82-116,(2006) ISBN 1-4051-1040-6
  22. Powell S.R.: *The antioxidant properties of zinc.* *J Nutr.*,130(5):1447S-54S,(2000).PMID: 10801958.
  23. Uysal Z., Akar N., Kemahli S., Dincer N., Arcasoy A.: *Deferoxamine and urinary zinc excretion in  $\beta$ -thalassemia major.* *Pediatr Hematol Oncol.*, 10(3):257-60, (1993). PMID: 8217542.
  24. Chausmer A.B.: *Zinc, Insulin and Diabetes .* *Journal of American college of Nutrition.*,17 (2):109-15, (1998). PMID: 9550453.
  25. Fraker P.J., King L.E., Laakko T., Vollmer T.L.: *The dynamic link between the integrity of the immune system and zinc status.* *J Nutr.*, 130(5 (I)):1399S-406S (2000). PMID: 10801951.
  26. Fraker, P.J., Jardieu P. and Cook J.: *Zinc deficiency and immune function.* *Arch Dermatol.*, 123(12):1699-701, (1987). PMID: 3120653.
  27. Wapnir R.A. : *Zinc deficiency, malnutrition and the gastrointestinal tract.* *J Nutr.*,130 (5S (I)):1388S-92S, (2000) PMID: 10801949.
  28. William R. B., "Zinc and immune system," in *Encyclopaedia of Immunology*, Elsevier, Amsterdam, The Netherlands, 2<sup>nd</sup> edition, 2515–2516, (2004)
  29. Olivieri N.F., Brittenham G.M.: *Iron chelating therapy and the treatment of thalassaemia.* *Blood.*, 89(3):739-61, (1997). PMID: 9028304.
  30. Cohen A.R., Galanello R., Piga A., Dipalma A., Vullo C., Tricta F.: *Safety profile of the oral iron chelator deferiprone: A multicenter study.* *Br J Haematol.* 108(2):305-12, (2002). PMID: 10691860.
  31. Shamshirsaz A.A., Bekheirnia M.R., Kamgar M., Pourzahedgilani N., Bouzari N., Habibzadeh M., Hashemi R., Shamshirsaz A.A., Aghakhani S., Homayoun H., Larijani B.: *Metabolic and endocrinologic complications in  $\beta$ -thalassaemia major: A multicenter study in Tehran.* *BMC Endocr Disord.*,3(1):4,( 2003).PMID:12914670.
  32. Haghshenas M, Zamani J. 1<sup>st</sup>ed.*Thalassemia.* Shiraz; Shiraz Medical University Publisher. 10-30, (1997) .(In Persian).
  33. Anderson JB. *Minerals.* In: KL Escott-Stump, S Krause, S Food, *Nutrition and Diet therapy.* 11<sup>th</sup> ed. Philadelphia; Sanders. 134-54, (2004).
  34. Carpentieri U., Myers J., Thorpe I., Daehner C.W., and Haggard M.E., *Zinc and Iron in normal and leukemic lymphocytes from children .* *Cancer Res.*, 46(2):981-4 (1986). PMID: 3455680.
  35. Kattamis C., Efremov G., Pootrakul S.: *Effectiveness of one tube osmotic fragility screening in detecting beta-thalassaemia trait.* *J Med Genet.* 18(4):266-70,( 1981). PMID: 7277419.
  36. Manglani M., Lokeshwar M.R., Vani V.G., Bhatia N., Mhaskar V.: *NESTROFT'--an effective screening test for beta thalassaemia trait.* *Indian Pediatr.* , 34(8):702-7, (1997). PMID: 9492398.
  37. Okwi A.L., Byarugaba W., Parkes A., Ocaido M. :*The Reliability of Sickling and Solubility Tests and Peripheral Blood Film Method for Sickle Cell Disease Screening at District Health Centers In Uganda.* *Clinics in Mother and Child Health.*, 7, 1:1205-1210 (2010).
  38. Mulchandani D.V., Fulare M..B, Zodpey S.P., Vasudeo ND.: *Prevalence and some epidemiological factors of beta thalassaemia trait in Sindhi community of Nagpur City, India.* *Indian J Public Health.*, 52(1):11-5 (2008). PMID: 18700715.
  39. Cotton F, Malaviolle X, Vertongen F, Gulbis B. *Evaluation of an automated capillary electrophoresis system in the screening for hemoglobinopathies.* *Clin Lab.*, 55(5-6):217-21 (2009). PMID: 19728555.
  40. Vatanavicharn S., Pringsulka P., Kritalugsana S., Phuapairoj P., Wasi P.: *Zinc and copper status in hemoglobin H disease and beta-thalassaemia/hemoglobin*

- E disease. *Acta Haematol.*, 68(4):317-20 (1982). PMID:6817576.
41. Mahyar A., Ayazi P., Pahlevan Ali-Asghar, Mojabi H, Sehat Mohammad-Reza and Javadi A.: Zinc and Copper Status in Children with Beta-Thalassemia Major. *Iranian Journal of Pediatrics*, 20(3):297-302,(2010). *Bioline International* [www.bioline.org.br/pdf?pe10044](http://www.bioline.org.br/pdf?pe10044).
  42. Al-Samarrai A.H., Adaay M.H., Al-Tikriti K.A., Al-Anzy M.M.: Evaluation of some essential element levels in thalassemia major patients in Mosul district, Iraq. *Saudi Med J*, 29(1):94-7,( 2008). PMID: 18176681.
  43. Wainscoat J.S: The haemoglobinopathies In: Hoffbrand AV and Lewis M . *Postgraduate haematology 4<sup>th</sup> edition* Great Britain, Oxford. Heinemann Medical Book (1999).
  44. Dispenzieri A : The thalassaemia syndromes and the haemoglobinopathies . In Tefferi A. *Primary Haematology* . Totowa New Jersey Humana Press, 41-64,( 2001). ISBN 978-0-89603-664-2.
  45. De Sanctis V., Vullo C., Katz M., Wonke B., Tanas R., Bagni B: Gonadal function in patients with beta-thalassaemia major. *J Clin Pathol.*, 41(2):133-7 ,( 1988). PMID: 3127428.
  46. Das N., Das Chowdhury T., Chattopadhyay A., Datta A.G.: Attenuation of oxidative stress-induced changes in thalassemic erythrocytes by vitamin E. *Pol Pharmacol.*, 56(1):85-96, (2004). PMID: 15047982.
  47. Bashir N.A.: Serum zinc and copper levels in sickle cell anemia and beta-thalassemia in north Jordan. *Ann Trop Paediatr.*, 15(4):291-3 (1995). PMID: 8687204.
  48. Fuchs G.J., Tienboon P., Linpisarn S., Nimsakul S., Leelapat P., Tovanabutra S., Tubtong V, DeWier M, Suskind RM.: Nutritional factors and thalassaemia major. *Arch Dis Child.*, 74(3):224-7 ,(1996). PMID: 8787427.
  49. Jensen C.E., Tuck S.M., Agnew J.E., Koneru S., Morris R.W., Yardumian A., Prescott E., Hoffbrand A.V., Wonke B.: High prevalence of low bone mass in thalassemia major. *Br J Haematol.*, 103(4):911-5,( 1998). PMID: 9886300.
  50. Moafi A., Mobaraki G., Taheri S.S., Heidarzadeh A., Shahabi I., Majidi F.: Zinc in thalassemic patients and its relation with depression. *Biol Trace Elem Res.*, 123(1-3):8-13,( 2008). PMID: 18338112.
  51. Brittenham G.M., Griffith, P.M., Nienhuis, A.W ., McLaren C.E., Young N.S., Tucker E.E., Allen C.J., Farrell D.E., Harris J.W.: Efficacy of deferoxamine in preventing complication of iron overload in patients with thalassemia major. *N Engl J Med.*, 331(9):567-73,( 1994). PMID:8047080
  52. Olivieri N.F., Nathan D.G., MacMillan J.H., Wayne A.S., Liu P.P., McGee A., Martin M., Koren G., Cohen A.R.: Survival in medically treated patients with homozygous  $\beta$  thalassemia. *N Engl J Med.*, 331(9):574-8,( 1994). PMID:8047081
  53. Ferrara M., Matarese, S.M., Borrelli, B., et al.: Cardiac involvement in beta-thalassemia major and beta-thalassemia intermedia. *Haemoglobin.*, 28(2):123-9,( 2004). PMID:15182054
  54. Camaschella C. and Cappellini, M.D.: Thalassemia intermedia. *Haematologica.*, 80(1):58-68,( 1995). PMID: 7758995.
  55. Prasad A. S., Ortega J., Brewer G. J., Oberleas D., and Schoomaker E. B.: Trace elements in sickle cell disease. *JAMA.*, 235(22):2396-8, (1976). PMID: 946645.
  56. Arcasoy A., Cavdar A., Cin S., Erten J., Babacan E., Gozdasoglu S., Akar N.: Effects of zinc supplementation on linear growth in beta-thalassemia [a new approach]. *Am J Hematol.*, 24(2):127-36, (1987). PMID: 3812466.
  57. Phebus C.K., Maciak B.J., Gloninger M.F., Paul H.S.: Zinc status of children with sickle cell disease: relationship to poor growth. *Am J Hematol.*, 29(2):67-73,( 1988). PMID: 3189304.
  58. Leonard M. B., Zemel B. S., Kawchak D. A.: Ohene- Frempong K., and Stallings V. A. : Plasma zinc status, growth, and maturation

- in children with sickle cell disease. *J Pediatr.*, 132(3: 1):467-71,( 1998). PMID: 9544903.
59. Consolini R., Calleri A., Legitimo A., Massei F.: Immunological Evaluation of patients with Beta-thalassaemia major. *Acta Haematol.*, 105(1):7-12, (2001). PMID: 11340247.
  60. Hasanato R.M.: Zinc and antioxidant vitamin deficiency in patients with severe sickle cell anemia. *Ann Saudi Med.*, 26(1):17-21, (2006). PMID: 16521870.
  61. Temiye E.O., Duke E.S., Owolabi M.A., Renner J.K.: Relationship between Painful Crisis and Serum Zinc Level in Children with Sickle Cell Anaemia. *Anemia.*,698586:7 ,(2011). PMID:21490764
  62. Whitten C.F.: Growth status of children with sickle cell anemia. *Am J Dis Child.*, 102:355–64,( 1961). PMID: 13784947.
  63. Jimenez C.T., Scott R.B., Henry L., Sampson C.C., Ferguson A.D. :Studies in sickle cell anemia: the effects of homozygous sickle cell disease on the onset of menarche, pregnancy, fertility, pubescent changes and body growth in Negro subjects. *Arch Pediatr Adolesc Med.*,111(5):497-504,(1966). doi:10.1001/archpedi.1966.02090080075005.
  64. Arcasoy A., Cavdar A.O: Changes of trace minerals (serum iron, zinc, copper and magnesium) in thalassemia. *Acta Haematol.*,53(6):341-6,(1975). PMID:808939
  65. McCormack M.K, Dicker L, Katz SH, Caleb M, McDaniels J, Humphery A, Buchert E, Lubin B.: Growth patterns of children with sickle-cell disease. *Hum Biol.*,48(3):429-37,(1976). PMID: 976968.
  66. Phebus C.K., Gloninger M.F., Maciak B.J.; Growth patterns by age and sex in children with sickle cell disease. *J Pediatr.*, 105(1):28-33,(1984). PMID: 6737145.
  67. Platt O.S., Rosenstock W., Espeland M.: Influence of sickle hemoglobinopathies on growth and development. *N Engl J Med.*, 311(1):7-12,(1984). PMID: 6727978.
  68. Stevens M.C., Maude G.H., Cupidore L., Jackson H., Hayes R.J., Serjeant G.R.: Prepubertal growth and skeletal maturation in children with sickle cell disease. *Pediatrics.*, 78(1):124-32,( 1986). PMID:3725483
  69. Cousins R.J., Hempe J.M. Zinc. In: Present knowledge in nutrition. 6th edn. Washington, DC: Nutrition Foundation. 251-260,(1990). ISBN 92-4-157228-0
  70. Burtis W.J.: Parathyroid hormone-related protein: structure, function, and measurement. *Clin Chem.*, 38(11): 2171-2183,( 1992). PMID: 1424107.
  71. Theodoridis C., Ladis V., Papatheodorou A., Berdousi H., Palamidou F., Evagelopoulou C., Athanassaki K., Konstantoura O., Kattamis C.: Growth and management of short stature in thalassaemia major. *J Pediatr Endocrinol Metab.*, 11(3):835-44,(1998). PMID: 10091154.
  72. Haslett CH, Chilves ER, HunterJA , Boon NA, Editora . Davidson’s principal and practice of medicine. 18<sup>th</sup> ed. USA: Churchill Livingstone.766-768, (1999). ISBN-10: 0443059446; ISBN-13: 978-0443059445.
  73. Nishiyama S., Kiwaki K., Miyazaki Y., and Hasuda T.: Zinc and IGF-1 concentration in pregnant women with anaemia before and after supplementation with iron and / or zinc. *J Am Coll Nutr.*,18(3):261-7,( 1999). PMID: 10376783.
  74. Zemel B.S., Kawchak D.A., Fung E., Ohene-Frempong B. K., and Stallings V. A.: Effect of zinc supplementation on growth and body composition in children with sickle cell disease. *Am J Clin Nutr.*, 75(2):300-7,( 2002). PMID: 11815322.
  75. Brown K. H., Peerson J. M., Rivera J., and Allen L. H.: Effect of supplemental zinc on the growth and serum zinc concentrations of prepubertal children: a meta-analysis of randomized controlled trials. *American Journal of Clinical Nutrition.*, 75(6): 1062–1071,( 2002). PMID: 12036814.

76. Belton, N.R.: Essential element deficiency and toxicity. *Clin. Pediatr. J.Ped.Neonat.*, 2:45-48,( 2005).
77. Lukenn JN. The thalassemia and related disorders. In: Richard Lee GR, Foester J, Lukens J, Parakeras F, Green J, Rodgers GM. *Wintrob's clinical hematology*. 18<sup>th</sup> ed. Philadelphia; Lippincott, Williams & Wilkins. 1406-35,( 1999).
78. Quirolo K, Vichinsky E. Hemoglobin disorders in: Behrman RE. *Nelson Textbook of Pediatrics*. 18<sup>th</sup> ed. Philadelphia; Saunders. 2033-9,( 2007).
79. Klevay L.M.: Iron overload can induce mild copper deficiency. *J Trace Elem Med Biol.*, 14(4):237-40, (2001). PMID: 11396784.
80. Nasr M.R., Ali S., Shaker M., Elgaby E.: Antioxidant micronutrients in children with thalassaemia in Egypt. *East Mediterr Health J.*, 8(4-5):490-5,(2002). PMID: 15603029.
81. Maret W., Sandstead H.: Zinc requirements and the risks and benefits of zinc supplementation. *J Trace Elem Med Biol.*, 20(1):3-18,(2006). PMID: 16632171.
82. Arcasoy A., Cavdar A., Cin S., Erten J., Babacan E., Gözdasoglu S., Akar N.. Effects of zinc supplementation on linear growth in  $\beta$ -thalassemia. *Am. J. Hematol.*, 24:127-136,(2006). PMID: 3812466.
83. Dogru U., Arcasoy A., Cavdar A.O.: Zinc Levels of Plasma, Erythrocyte, Hair and Urine in Homozygote Beta-Thalassemia. *Acta Haematol.*, 62:1;41-44,(1979) (DOI: 10.1159/000207534).
84. Rea F., Perrone L., Mastrobuono A., Toscano G., D'Amico M.: Zinc levels of serum, hair and urine in homozygous beta-thalassemic subjects under hypertransfusional treatment. *Acta Haematol.*, 71:139-142,( 1984). PMID: 6421055.
85. Silprasert A., Laokuldilok T., Kulapongs P.: Zinc deficiency in beta thalassaemia children . *Birth Defects Orig Artic Ser.*, 23(5A):473-6,(1987). PMID:3689934
86. Adman H: Zinc deficiency in thalassemia. *J clin Nutr.*, 45:1313-1322,( 1987).
87. Moghadam A, Izadyar M, Samii SH: Alteration of serum trace elements (Zn, Cu, Mg) in beta-thalassemia major patients under desferal therapy. *Iran J Blood Transf.*, 4:180-188,( 1998).
88. Caruso Nicoletti M., De Sanctis V., Cavallo L., Raiola G., Ruggiero L., Skordis N., Wonke B.: International Workshop on Management of Puberty for Optimum Auxological Results. Management of puberty for optimal auxological results in beta-thalassaemia major. *J Pediatr Endocrinol Metab.*, 14 (2):939-44,( 2001). PMID: 11529399.
89. Faranoush, M., M. Rahiminejad, Z. Karamizadeh, R. Ghorbani and S.M. Owji,. Zinc supplementation effect on linear growth in transfusion dependent  $\beta$ -thalassemia. *IJBC.*, 1 (1) :29-32,( 2008).
90. Arcasoy A., Canata D., Sinav B., Kutlay L., Oguz N., Sen M.: Serum Zinc Levels and Zinc binding capacity in thalassemia. *J Trace Elem Med Biol.*, 15(2-3):85-7,( 2001). PMID: 11787992.
91. Mehdizadeh M., Zamani G, Tabatabaee S.: Zinc status in patients with major  $\beta$ -thalassemia. *Pediatr Hematol Oncol.* 25(1):49-54,( 2008). PMID: 18231954.
92. Arcasoy A., Cavdar A.O: Growth retardation in beta-thalassemia. *J Pediatr.*, 99(4):671-2,( 1981) . PMID: 7277125.
93. Yazdiha M.S., Faranoush M.: Assessment of serum Zinc concentration in Thalassemia major children. *Pejouhesh.*, 27:1;23-5,( 2003).
94. Moayeri H., Oloomi Z.: Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major. *Arch Iran Med.*, 9(4):329-34,( 2006). PMID: 17061604.
95. Prasad Ananda S., Diwany M., Gabr M., Sandstead Harold H., Mokhtar N., Hefny Anisa E.L.: Biochemical Studies in Thalassemia. *Ann Intern Med.*, 62:87-96,( 1965). PMID:14258353
96. Hamid M.O. and Pradhan P.S. : Study of trace elements in splenectomized beta

- thalassaemia major children . Indian J Haematol Blood tran. 17(4):92-4,( 1999).
97. Kwan, E.Y., Lee A.C. and Li A.M., A cross sectional study of growth, puberty and endocrine function in thalassemia major in Hong Kong. J Paediatr Child Health.,31(2):83-7,(1995) . PMID: 7794630.
98. Kajanachumpol S., Tatu T., Sasanakul W., Chuansumrit A., Hathirat P.: Zinc and copper status of thalassemia children. Southeast Asian J Trop Med Public Health., 28(4):877-80,( 1997). PMID: 9656419.
99. Tabatabaei M, Kamkar M, Habibzadeh MR. Metabolic and endocrine complications in beta-thalassemia major; a multicenter study in Tehran. Boshehr Med J.,5(1):72-73,( 2003). (In Persian).
100. Kassab-Chekir A., Laradi S., Ferchichi S., Haj Khelil A., Feki M., Amri F., Selmi H., Bejaoui M., Miled A. : Oxidant/anti-oxidant status and metabolic data in patients with beta-thalassemia. Clin Chim Acta.,338(1-2):79-86,( 2003). PMID: 14637270.
101. Yazdideha M.S., Faranosh M.: Evaluation of serum zinc in children affected with beta-thalassemic patients. Res Med., 24(1):7-9,( 2004).
102. Eshghi P., Alavi S., Ghavami S., Rashidi A.: Growth impairment in beta-thalassemia major: the role of trace element deficiency and other potential factors. J Pediatr Hematol Oncol., 29(1): 5-8,( 2007). PMID: 17230059.
103. Claster S., Wood J.C., Noetzli L., Carson S.M., Hofstra T.C., Khanna R., Coates T.D.: Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. Am J Hematol., 84(6):344-8,( 2009). PMID: 19415722.
104. Hashempour Mahin, Modaresi M.R., Sepah Vand N.,Shahabi I., Ahmadianiar A. :Zinc concentration in thalassemic patient's hair. J Med Faculty Guilan Uni Med Sci.,33(9):74-8,( 2000). (In Persian)
105. Erlandson M.E., Golubow J., Wehran T., Smith C.H.: Metabolism of iron , calcium and magnesium in homozygous thalassaemia . Annals of the New York Academy of Sciences. Problems of Cooley's Anemia., 119, 769–775,( 1964). PMID: 14219456.
106. Erlandson M.E., Golubow J., and Smith C.H: Bivalent cation in homozygous thalassaemia. J Pediatr., 66:637-48,( 1965). PMID: 14264319.
107. William W.J. , Beutler E., Erslev A.J., Rundles R.W : ed . New York McGraw Hill.360,( 1972).
108. Tanphaichitr V.S., Visuthi V. and Tanphaichitr V. :Causes of inadequate protein-energy status in thalassaemic children. Asia Pac. J. Clin. Nutr., 4:133-135,( 1995).
109. Oktekin R., Gokmen G.: Iron, Zinc, Copper levels of thalassemia patients of northern Cyprus. Trace Elem Man Animals., 10:3:627-628,( 2000). DOI: 10.1007/0-306-47466-2\_199. ISBN-10: 0306463784.
110. Alexander, H.D., Sherlock J.B. and Bharucha C.: Red cell indices as predictors of iron depletion in blood donors. Clin Lab Haematol., 22(5):253-8,( 2000).PMID:11122264.
111. Kamal M., Talal A., Moussa B. and Hamzeh N. Copper and Zinc status in Jordanian patients with  $\alpha$ - thalassaemia Major Treated with Deferoxamine. Research Journal of Biological Sciences.,4(5):556-572,( 2009). doi=rjbsci.2009.566.572.
112. Eleftheriou, A. Iron Overloads and Iron Chelation, about Thalassemia. Thalassemia International Federation, USA.38-61,(2003).
113. Uysal Z., Akar N., Kemahli S., Dincer N., Arcasoy A.: Deferoxamine and urinary zinc excretion in  $\beta$ -thalassemia major. Pediatr Hematol Oncol., 10(3):257-60,(1993). PMID:8217542.
114. Suthipark, K.U.: Red cell and plasma calcium, copper and zinc in  $\beta$ -thalassemia/hemoglobin E. Southeast Asian J. Trop. Med. Pubic Health., 22(2):171-5,( 1991). PMID: 1948275.
115. Al-Sayer H., Dashti H., and Christenson J., et al: The role of superoxide dismutase and allupurinal in the prevention of CCl4 induced liver cirrhosis. In: Abdulla M.,

Dashti H, Sarkar B., Al-Sayer H. and Al-Naqeeb N. Metabolism of minerals and trace elements in human disease. 1<sup>st</sup> ed. New Delhi, India Smith-Gordon and Company Limited. 65-85,( 1989).

116. Tavazzi D., Duca L., Graziadei G., Lomino A., Fiorehi G., and Coppelini MD.: Membrane-bound iron contributes to oxidative damage of beta-thalassaemia intermedia erythrocytes. Br J Haematol., 112(1):48-50,( 2001). PMID: 11167782.
117. Arora R.B., Hameed A., and Subramanian et al: Differential serum zinc concentration in some cardiovascular diseases and bronchial asthma. In: Abdulla M, Dashti H, Sarkar B, Al-Sayer H, and Al-Naqeeb N. Metabolism of minerals and trace elements in human disease. 1<sup>st</sup> ed. New Delhi, India. Smith-Gordon and Company Limited. 57-60,( 1989).